-+ 0.00%
-+ 0.00%
-+ 0.00%

Lytix Biopharma Plans NOK 60-80 Million Private Placement

PUBT·11/17/2026 15:34:39
Listen to the news
Lytix Biopharma Plans NOK 60-80 Million Private Placement
  • Lytix Biopharma plans to raise NOK 60-80 million through a private placement priced at NOK 8 per share.
  • Shareholders pre-committed approximately NOK 60 million; a Norwegian retail offering targets up to the NOK equivalent of EUR 1 million.
  • Proceeds will fund ruxotemitide Phase III preparations, the ALETTA Phase II study and other development and working capital needs.
  • The Phase III study itself will require additional financing or a partnership before initiation.
  • Cash runway is expected to extend into the fourth quarter of 2027, assuming Phase III initiation awaits additional financing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma ASA published the original content used to generate this news brief via Cision (Ref. ID: 20261117:BIT:0505:0) on November 17, 2026, and is solely responsible for the information contained therein.